IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess)

First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabellar lines) beyond 6 months
These results reinforce RelabotulinumtoxinA’s 6-month clinical effect and rapid onset from Day 1 demonstrated in the phase III READY clinical trial program1,2
Data also show high and sustained patient satisfaction with treatment outcomes and appearance beyond 6 months1
Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator developed using PEARLTM Technology that is optimized for simple volumetric dosing to increase ease-of-use3,4,5

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025.

Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule3,4,5. Previously announced data from the phase III READY clinical trial program demonstrated rapid onset as soon as Day 1 (reported by up to 39% of subjects) and long-lasting efficacy for 6 months (maintained by up to 75% of subjects) when using RelabotulinumtoxinA to treat frown lines and crow’s feet (lateral canthal lines) 2,6.